United States· US:0456-1512_3d53a938-bbb3-410c-a754-3ed1de4f8840

Savella

A milnacipran product containing milnacipran hydrochloride, registered in United States by Allergan, Inc.. The same ATC class is registered in 6 of our 19 countries.

ATC N06AX17

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedSavellaATCN06AX17REGISTER NO.US:0456-1512_3d53a938…PACKS LISTED1CHECKEDAugust 23, 2026

Where it is registered

Milnacipran is registered in 6 of 19 countries.

Countries holding a registration under ATC N06AX17 (milnacipran), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 3 of them publish a price we can compare per daily dose

Milnacipran · ATC N06AX17

6 / 19 countries

  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of milnacipran costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.

  • United States: $24.47 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Milnacipran · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • US United States$24.47 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
MILNACIPRAN HYDROCHLORIDE
Manufacturer
Allergan, Inc.
Country
United States (US)
ATC code
N06AX17
ATC class
Milnacipran
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
August 23, 2026

Packs & prices · 1

  • ndc11
    0456-1512-60

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

194 interactions on record for milnacipran.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Milnacipran · interactions on record

194 records

  • 27 severe
  • 167 moderate

Most severe, free to view

  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • PalonosetronA04AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Milnacipran in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All milnacipran products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Austria · Milnacipran Glenmark, Milnacipran Rivopharm
  • Germany · Milnacipran Glenmark, Milnacipran Holsten
  • France · Milnacipran Arrow, Milnacipran Eg
  • Luxembourg · Milnacipran Micro Labs

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/067d1be6-1f64-4fdb-8b5d-dc4c3d3aec76
GET /v1/drugs/067d1be6-1f64-4fdb-8b5d-dc4c3d3aec76?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "12.5",
  "substance": "MILNACIPRAN HYDROCHLORIDE",
  "productndc": "0456-1512",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA022256",
  "marketing_category": "NDA"
}

See everything about milnacipran.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.